Cartesian Therapeutics, Inc. (RNAC)
(Delayed Data from NSDQ)
$16.85 USD
+0.69 (4.27%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.84 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RNAC 16.85 +0.69(4.27%)
Will RNAC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RNAC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RNAC
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
RNAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
What Makes Cartesian Therapeutics, Inc. (RNAC) a New Buy Stock
Wall Street Analysts Think Cartesian Therapeutics, Inc. (RNAC) Could Surge 141%: Read This Before Placing a Bet
Other News for RNAC
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis